Miranda Jayne Toledano - Sep 7, 2022 Form 4 Insider Report for Entera Bio Ltd. (ENTX)

Role: Chief Executive Officer, Director
Signature: /s/ Dana Yaacov-Garbeli, Attorney-in-Fact
Stock symbol: ENTX
Transactions as of: Sep 7, 2022
Transactions value $: $0
Form type: 4
Date filed: 9/9/2022, 04:07 PM
Previous filing: Jul 25, 2022
Next filing: Nov 14, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ENTX	Stock Option (right to buy)	Award	$0	+500K		$0.00	500K	Sep 7, 2022	Ordinary Shares, par value NIS 0.0000769 per share	500K	$2.02	Direct	F1
transaction	ENTX	Stock Option (right to buy)	Award	$0	+600K		$0.00	600K	Sep 7, 2022	Ordinary Shares, par value NIS 0.0000769 per share	600K	$1.40	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This grant of options was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on May 11, 2022, subject to approval by the Company's shareholders, which was obtained on September 7, 2022. The options vest over a four-year period that commenced on May 16, 2022, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.
F2	This grant of options was approved by the Board on July 15, 2022, subject to approval by the Company's shareholders, which was obtained on September 7, 2022. The options vest over a four-year period that commenced on July 15, 2022, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.

Content

This grant of options was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on May 11, 2022, subject to approval by the Company's shareholders, which was obtained on September 7, 2022. The options vest over a four-year period that commenced on May 16, 2022, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.

This grant of options was approved by the Board on July 15, 2022, subject to approval by the Company's shareholders, which was obtained on September 7, 2022. The options vest over a four-year period that commenced on July 15, 2022, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.